Pasithea Therapeutics posts investor presentation on PAS-004 program
KTTA•Investor presentation outlines PAS-004 development plans
Pasithea Therapeutics published an investor presentation outlining development plans for lead MEK inhibitor candidate PAS-004.
The clinical program centers on two Phase 1 studies: PAS-004-102 in MAPK-pathway solid tumors, and PAS-004-103 in adult NF1 plexiform neurofibromas.
Interim updates are flagged for ESMO Congress 2026 for the cancer study, and Q4 2026 for NF1 Part A data covering PN and CN.
The financial snapshot lists a market cap of $19.2 million and a cash balance of $45.6 million as of 6/30/26.
